Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Ironwood Pharmaceuticals
IRWD
Market cap
$262M
Overview
Fund Trends
Analyst Outlook
Journalist POV
1.61
USD
+0.13
8.78%
At close
Updated
Oct 15, 4:00 PM EDT
Pre-market
After hours
1.66
+0.05
3.11%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
8.78%
5 days
1.26%
1 month
25.78%
3 months
134.35%
6 months
122.93%
Year to date
-62.82%
1 year
-63.33%
5 years
-83.98%
10 years
-83.23%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
16.7%
Negative
Positive
Neutral
Negative
Positive
Zacks Investment Research
yesterday
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Positive
Zacks Investment Research
yesterday
Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
2 months ago
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
Positive
The Motley Fool
2 months ago
Ironwood (IRWD) Q2 EPS Jumps 600%
Ironwood (IRWD) Q2 EPS Jumps 600%
Positive
Zacks Investment Research
2 months ago
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a year ago.
Neutral
Business Wire
2 months ago
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. “In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand growth of 10% year-over-year. Additionally, LINZESS net price was in-line with our expectations for the qu.
Negative
Zacks Investment Research
4 months ago
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
Negative
Zacks Investment Research
5 months ago
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Negative
Zacks Investment Research
5 months ago
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.
Neutral
Business Wire
5 months ago
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close